NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase 2
Completed
- Conditions
- Epithelial MesotheliomaLocalized Malignant MesotheliomaSarcomatous MesotheliomaAdvanced Malignant MesotheliomaRecurrent Malignant Mesothelioma
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00309946
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
Phase 2
Completed
- Conditions
- Stage IA Pancreatic CancerStage IB Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic Cancer
- Interventions
- Biological: cetuximabRadiation: radiation therapyBiological: bevacizumabOther: laboratory biomarker analysis
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 137
- Registration Number
- NCT00305877
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Vorinostat in Treating Patients With Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Recurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Refractory Cytopenia With Multilineage Dysplasia
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00305773
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 1
Completed
- Conditions
- Adult GlioblastomaAdult GliosarcomaAdult Giant Cell Glioblastoma
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2018-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 118
- Registration Number
- NCT00305864
- Locations
- 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2
Completed
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00305656
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
Phase 2
Completed
- Conditions
- Recurrent Nasopharyngeal CancerStage IV Nasopharyngeal Cancer
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00305734
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance
Not Applicable
Completed
- Conditions
- Overweight
- Interventions
- Dietary Supplement: Decaffeinated coffeeDietary Supplement: No coffeeDietary Supplement: Caffeinated coffee
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2018-03-06
- Target Recruit Count
- 45
- Registration Number
- NCT00305097
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Recurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell Lymphoma
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00303953
- Locations
- 🇺🇸
Heartland Regional Medical Center, Saint Joseph, Missouri, United States
🇺🇸Kalispell Medical Oncology, Kalispell, Montana, United States
🇺🇸Kalispell Regional Medical Center, Kalispell, Montana, United States
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
Phase 2
Terminated
- Conditions
- Recurrent Renal Cell CancerStage IV Renal Cell CancerClear Cell Renal Cell Carcinoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00303862
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
Phase 2
Completed
- Conditions
- Cervical CancerCervical Intraepithelial Neoplasia Grade 1Human Papilloma Virus Infection
- Interventions
- Dietary Supplement: defined green tea catechin extractDrug: placeboOther: laboratory biomarker analysis
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 98
- Registration Number
- NCT00303823
- Locations
- 🇺🇸
Arizona Cancer Center - Tucson, Tucson, Arizona, United States